Par Pharmaceutical
Companies, Inc. today announced that its operating subsidiary, Anchen
Pharmaceuticals, Inc., has received final approval from the U.S. Food and Drug
Administration for its Abbreviated New Drug Application for tretinoin
capsules, 10 mg. Tretinoin capsules is the generic version of Vesanoid^®
capsules and is used in the treatment of acute promyelocytic leukemia. Par
expects to begin shipping the product before the end of the month.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in